[{"id":"05a7a7b4-9b3e-4998-8177-af641d62afb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04386967","created_at":"2021-01-18T21:10:40.399Z","updated_at":"2024-07-02T16:35:48.866Z","phase":"Phase 1/2","brief_title":"OH2 Injection in Solid Tumors","source_id_and_acronym":"NCT04386967","lead_sponsor":"Binhui Biopharmaceutical Co., Ltd.","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • BS001"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 03/13/2024","primary_completion_date":" 03/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2023-05-05"},{"id":"77fa5f49-487a-4db1-b519-6ab7e22a9571","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616443","created_at":"2021-01-19T20:33:37.345Z","updated_at":"2024-07-02T16:35:56.720Z","phase":"Phase 1/2","brief_title":"OH2 Injection in Combination With HX008 for Melanoma.","source_id_and_acronym":"NCT04616443","lead_sponsor":"Binhui Biopharmaceutical Co., Ltd.","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • BS001"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-01-31"}]